pISSN:2349-5707 Volume:13,Issue 3, March -2026 eISSN:2349-5715

ANTIBIOTIC RESISTANCE IN TUBERCULOSIS MICROBIOLOGICAL MECHANISMS, CLINICAL IMPACT, AND GLOBAL CHALLENGES

Shahbaz Israr
Samarkand State Medical University
Student of the International Educational Faculty
e-mail: moshahwaz706090@gmail.com , +998990479655
Odilova Nilufar Arzikulovna
Samarkand State Medical University
Assistant Teacher- Microbiology, Virology and Immunology Department
e-mail: nilufarodilova9999@gmail.com , +998979159901

Abstract

Tuberculosis (TB), an ancient scourge caused by Mycobacterium tuberculosis, remains a leading global infectious killer. The emergence of antibiotic-resistant strains—multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB)—has escalated into a defining public health crisis. This resistance stems not from simple horizontal gene transfer but from a complex interplay of spontaneous bacterial mutations and systemic human failures in treatment delivery. This article examines the unique microbiological mechanisms that allow TB to evade our drugs, the severe clinical consequences for patients and societies, and the multifaceted global challenges that fuel this epidemic. Understanding this triad is essential for forging effective therapeutic strategies and regaining control in the fight against TB.

Introduction:

Tuberculosis has haunted humanity for millennia, primarily attacking the lungs but capable of affecting any organ. Despite the advent of curative antibiotic regimens in the mid-20th century, TB persists as a massive burden, with the World Health Organization reporting an estimated 10.6 million new cases and 1.3 million deaths in 2022 (2). A significant and growing portion of these cases now involves drug-resistant forms, undermining decades of progress.

Critically, antibiotic resistance in TB follows a different rulebook than in common bacterial infections. M. tuberculosis acquires resistance primarily through spontaneous chromosomal mutations that are then selected for when antibiotic pressure is inconsistent or inadequate. Factors like incorrect prescriptions, incomplete treatment courses, and delayed diagnostics create the perfect environment for resistant mutants to thrive. The rise of MDR and XDR-TB transforms a curable disease into a protracted, toxic, and often fatal ordeal, making the study of its resistance not just a microbiological curiosity but a clinical and ethical imperative.

The Bacterial Fortress: Unique Traits of M. tuberculosis

TB's intrinsic hardiness lays the groundwork for acquired resistance. Key features include:

· A thick, lipid-rich cell wall containing mycolic acids, acting as a formidable barrier to drug penetration.

· An extremely slow growth rate, rendering many antibiotics that target rapid cell division less effective.

· The ability to survive inside human macrophages, hiding from both the immune system and some drugs.

pISSN:2349-5707 Volume:13,Issue 3, March -2026 eISSN:2349-5715

· A dormant or "persister" state, leading to latent infection and requiring prolonged treatment, which increases the window for resistance to develop.

These traits make TB inherently tough to treat and facilitate the selection of resistant mutants during the long course of therapy.

The Mechanisms of Evasion: How TB Outsmarts Each Drug

Resistance in TB is primarily driven by point mutations in specific genes. Each first-line drug has its own Achilles' heel:

· Isoniazid (INH): A prodrug requiring activation by the bacterial enzyme KatG. Resistance commonly occurs through katG mutations (preventing activation) or inhA mutations (altering the drug target).

· Rifampicin (RIF): Inhibits RNA polymerase. Mutations in the rpoB gene change the drug's binding site, causing high-level resistance. Rifampicin resistance is a critical proxy for MDR-TB.

· Ethambutol: Targets cell wall synthesis. Mutations in the embB gene are frequently linked to resistance.

· Pyrazinamide: Requires conversion to its active form by the bacterial enzyme PncA. Mutations in the pncA gene disrupt this activation.

The Spectrum of Resistance: From MDR to XDR

· Multidrug-Resistant TB (MDR-TB): Defined as resistance to at least both isoniazid and rifampicin, the two most potent first-line drugs. Treating MDR-TB forces a shift to longer, more complex regimens using second-line drugs.

· Extensively Drug-Resistant TB (XDR-TB): Defined as MDR-TB plus resistance to any fluoroquinolone (e.g., moxifloxacin) and at least one second-line injectable (e.g., amikacin). This leaves patients with virtually no reliable treatment options, resulting in historically high mortality rates.

Resistance to these second-line agents follows similar genetic principles—mutations in gyrA/gyrB for fluoroquinolones and in the rrs gene for injectables like amikacin.

The Human Factor: How Treatment Failures Fuel Resistance

The microbiology is only half the story. Resistance is dramatically amplified by socio-clinical factors:

· Incomplete or irregular drug intake due to lack of support or education.

· Severe adverse drug effects leading to premature treatment stoppage.

· Drug stockouts and inconsistent supply chains.

· Inappropriate prescribing or dosing by healthcare providers.

These factors create the "selective pressure" that allows a single resistant bacterium to multiply and become the dominant population in a patient (7).

The Diagnostic Dilemma: The Critical Delay

pISSN:2349-5707 Volume:13,Issue 3, March -2026 eISSN:2349-5715

Timely diagnosis of resistance is paramount but fraught with obstacles. Traditional methods rely on sputum culture and drug susceptibility testing (DST), a process taking weeks to months. During this delay, patients may be on ineffective regimens, worsening outcomes and transmission. The advent of rapid molecular tests (like GeneXpert MTB/RIF and line probe assays) that detect TB and key resistance mutations within hours has been a game-changer, yet access in high-burden, resource-limited settings remains uneven (8).

The Devastating Toll: Clinical and Public Health Impact

The consequences of drug-resistant TB are profound:

· For the Patient: Treatment extends to 18-24 months or more with 6-8 drugs that are less effective, more toxic (causing hearing loss, psychosis, hepatitis), and exponentially more expensive. Cure rates drop, and mortality risks soar.

· For the Community: Patients remain infectious for longer, spreading resistant strains. The economic burden on families and healthcare systems is crushing.

· Globally: XDR-TB is a threat to all, undermining global health security and reversing hard-won gains in TB control (1, 6).

The Path Forward: Strategies to Combat Resistance

Addressing this crisis requires a multi-pronged attack:

1. Strengthen the Basics: Ensure universal access to Directly Observed Therapy, Short-course (DOTS) for drug-sensitive TB to prevent new resistance from forming.

2. Diagnose Rapidly and Accurately: Scale up rapid molecular testing to guide appropriate treatment from day one (8).

3. Treat Effectively with New Tools: Utilize newer drugs like bedaquiline, delamanid, and pretomanid within shorter, all-oral regimens for MDR-TB, as recommended by the WHO, managed carefully to protect their efficacy (9).

4. Invest in Research: Accelerate development of novel antibiotics, host-directed therapies, and an effective vaccine.

5. Build Resilient Systems: Address poverty, stigma, and weak health infrastructure that allow TB to flourish (10).

Conclusion

Antibiotic resistance in tuberculosis represents a perfect storm of microbial ingenuity and systemic human failure. It is a phenomenon rooted in the unique biology of Mycobacterium tuberculosis and catastrophically amplified by gaps in our healthcare delivery and global equity. Combating it demands more than just new drugs; it requires a steadfast commitment to accurate diagnostics, uninterrupted treatment access, and robust public health systems. The battle against TB is now a race against resistance—one that we cannot afford to lose.

References

1. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. (Provides comprehensive epidemiological data, including burden of DR-TB).

pISSN:2349-5707 Volume:13,Issue 3, March -2026 eISSN:2349-5715

2. Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291-360. (A seminal review covering mechanisms, impact, and management of MDR/XDR-TB).

3. Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017;41(3):354-373. (Details the microbiological and genetic basis of resistance).

4. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013;12(5):388-404. (Discusses TB bacteriology and the challenges it poses for drug development).

5. Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55(5):2032-2041. (Links specific genetic mutations to phenotypic resistance for key drugs).

6. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375(9728):1830-1843. (Classic article defining the clinical and public health crisis of XDR-TB).

7. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38(3):516-528. (Highlights the programmatic and patient-care factors contributing to and addressing DR-TB).

8. World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3: Diagnosis – rapid diagnostics for tuberculosis detection. 2021 update. Geneva: World Health Organization; 2021. (Current guidelines on rapid molecular diagnostics for TB and resistance).

9. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. (Authoritative source on modern, shorter regimens for MDR-TB including new drugs).

10. Uplekar M, Weil D, Lonnroth K, et al. WHO's new End TB Strategy. Lancet. 2015;385(9979):1799-1801. (Outlines the holistic framework necessary to combat TB, including DR-TB, through strengthened health systems and social protection).